Citations (104)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Matthias Egger, Romuald Bellmann, Robert Krause, Johannes Boyer, Daniela Jakšić & Martin Hoenigl. (2023) Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations. Infection and Drug Resistance 16, pages 2167-2178.
Read now
Read now
Diego R. Falci, Franciane B. da Rosa & Alessandro C. Pasqualotto. (2015) Hematological toxicities associated with amphotericin B formulations. Leukemia & Lymphoma 56:10, pages 2889-2894.
Read now
Read now
Angela S Loo, Saif A Muhsin & Thomas J Walsh. (2013) Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B
. Expert Opinion on Drug Safety 12:6, pages 881-895.
Read now
Read now
Jamil N. Kanji, Michel Laverdière, Coleman Rotstein, Thomas J. Walsh, Prakesh S. Shah & Shariq Haider. (2013) Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials. Leukemia & Lymphoma 54:7, pages 1479-1487.
Read now
Read now
Necdet Kuyucu. (2011) Amphotericin B use in children: conventional and lipid-based formulations. Expert Review of Anti-infective Therapy 9:3, pages 357-367.
Read now
Read now
Charles Craddock, James Anson, Patrick Chu, Andrew Dodgson, Nick Duncan, Cesar Gomez, Jayesh Mehta, Shalal Sadullah, Chinari Subudhi & John-Liu Yin. (2010) Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex. Expert Opinion on Drug Safety 9:1, pages 139-147.
Read now
Read now
Jörg J Vehreschild, Maria JGT Rüping, Angela Steinbach & Oliver A Cornely. (2010) Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. Expert Opinion on Pharmacotherapy 11:1, pages 95-113.
Read now
Read now
Patrick Chu & Shalal Sadullah. (2009) The current role of amphotericin B lipid complex in managing systemic fungal infections. Current Medical Research and Opinion 25:12, pages 3011-3020.
Read now
Read now
PH Chandrasekar. (2008) Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Therapeutics and Clinical Risk Management 4:6, pages 1285-1294.
Read now
Read now
Faouzi Saliba & Bertrand Dupont. (2008) Renal impairment and Amphotericin B formulations in patients with invasive fungal infections. Medical Mycology 46:2, pages 97-112.
Read now
Read now
D. Pacini, M. Cerana, A. Beltrame, A. Di Biagio & A. De Maria. (2007) Persistence of Candida albicans Candidemia in Non-Neutropenic Surgical Patients: Management of a Representative Patient in the Absence of Second-Line Treatment Guidelines. Journal of Chemotherapy 19:3, pages 335-338.
Read now
Read now
Joshua Perlroth, Bryan Choi & Brad Spellberg. (2007) Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Medical Mycology 45:4, pages 321-346.
Read now
Read now
Winter J Gibbs, Richard H Drew & John R Perfect. (2005) Liposomal amphotericin B: clinical experience and perspectives. Expert Review of Anti-infective Therapy 3:2, pages 167-181.
Read now
Read now
Jason C Gallagher, Conan MacDougall, Elizabeth S Dodds Ashley & John R Perfect. (2004) Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert Review of Anti-infective Therapy 2:2, pages 253-268.
Read now
Read now
Rodrigo Martino. (2004) Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Current Medical Research and Opinion 20:4, pages 485-504.
Read now
Read now
Peter K Linden. (2003) Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opinion on Pharmacotherapy 4:11, pages 2099-2110.
Read now
Read now
John H Rex & Sevtap Arikan. (2002) New agents for the treatment of systemic fungal infections – current status. Expert Opinion on Emerging Drugs 7:1, pages 3-32.
Read now
Read now
Articles from other publishers (87)
Michelle H. Ting, Andrej Spec, Scott T. Micek, David J. Ritchie & Tamara Krekel. (2021) Evaluation of Total Body Weight versus Adjusted Body Weight Liposomal Amphotericin B Dosing in Obese Patients. Antimicrobial Agents and Chemotherapy 65:9.
Crossref
Crossref
Martin Hoenigl, Jon Salmanton-García, Thomas J Walsh, Marcio Nucci, Chin Fen Neoh, Jeffrey D Jenks, Michaela Lackner, Rosanne Sprute, Abdullah M S Al-Hatmi, Matteo Bassetti, Fabianne Carlesse, Tomas Freiberger, Philipp Koehler, Thomas Lehrnbecher, Anil Kumar, Juergen Prattes, Malcolm Richardson, Sanjay Revankar, Monica A Slavin, Jannik Stemler, Birgit Spiess, Saad J Taj-Aldeen, Adilia Warris, Patrick C Y Woo, Jo-Anne H Young, Kerstin Albus, Dorothee Arenz, Valentina Arsic-Arsenijevic, Jean-Philippe Bouchara, Terrence Rohan Chinniah, Anuradha Chowdhary, G Sybren de Hoog, George Dimopoulos, Rafael F Duarte, Petr Hamal, Jacques F Meis, Sayoki Mfinanga, Flavio Queiroz-Telles, Thomas F Patterson, Galia Rahav, Thomas R Rogers, Coleman Rotstein, Retno Wahyuningsih, Danila Seidel & Oliver A Cornely. (2021) Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. The Lancet Infectious Diseases 21:8, pages e246-e257.
Crossref
Crossref
Francelise B. Cavassin, João Luiz Baú-Carneiro, Rogério R. Vilas-Boas & Flávio Queiroz-Telles. (2021) Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infectious Diseases and Therapy 10:1, pages 115-147.
Crossref
Crossref
Fernanda Wirth & Kelly Ishida. (2020) Antifungal drugs: An updated review of central nervous system pharmacokinetics. Mycoses 63:10, pages 1047-1059.
Crossref
Crossref
Alison G. Freifeld & Daniel R. Kaul. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
544
564.e6
.
Shahid Husain & Jose F. Camargo. (2019) Invasive Aspergillosis in solid‐organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 33:9.
Crossref
Crossref
Nikolaos Spernovasilis & Diamantis Kofteridis. (2018) Pre-Existing Liver Disease and Toxicity of Antifungals. Journal of Fungi 4:4, pages 133.
Crossref
Crossref
Emma Bagshaw, David A Enoch, Michael Blackney, Jan Posthumus & Daniel Kuessner. (2018) Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. Future Microbiology 13:11, pages 1283-1293.
Crossref
Crossref
Ritam Sidhu, David B. Lash, Arash Heidari, Piruthiviraj Natarajan & Royce H. Johnson. (2018) Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis. Antimicrobial Agents and Chemotherapy 62:7.
Crossref
Crossref
Luiza Raquel Grazziotin, Leila Beltrami Moreira & Maria Angelica Pires Ferreira. (2018) COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW. International Journal of Technology Assessment in Health Care 34:3, pages 343-351.
Crossref
Crossref
Romuald Bellmann & Piotr Smuszkiewicz. (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45:6, pages 737-779.
Crossref
Crossref
Anthony J. Perissinotti & Bernard L. Marini. (2017) Real-Life Challenges to the Use of Antifungal Agents in Hematology Patients. Current Fungal Infection Reports 11:4, pages 229-241.
Crossref
Crossref
Fernanda S Tonin, Laiza M Steimbach, Helena H Borba, Andreia C Sanches, Astrid Wiens, Roberto Pontarolo & Fernando Fernandez-Llimos. (2017) Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. Journal of Pharmacy and Pharmacology 69:12, pages 1672-1683.
Crossref
Crossref
Raquel Fernández-García, Esther de Pablo, María Paloma Ballesteros & Dolores R. Serrano. (2017) Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting. International Journal of Pharmaceutics 525:1, pages 139-148.
Crossref
Crossref
Laiza M. Steimbach, Fernanda S. Tonin, Suzane Virtuoso, Helena H. L. Borba, Andréia C. C. Sanches, Astrid Wiens, Fernando Fernandez-Llimós & Roberto Pontarolo. (2017) Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis. Mycoses 60:3, pages 146-154.
Crossref
Crossref
R Moghnieh, I Fawaz, A Mugharbil, T Jisr, D Abdallah & A Ibrahim. (2015) Clinical outcome and adverse events associated with empiric and pre-emptive use of amphotericin B lipid complex in a single center in lebanon. Bone Marrow Transplantation 51:4, pages 598-600.
Crossref
Crossref
Rima Moghnieh, Nabila El-Rajab, Dania Issam Abdallah, Ismail Fawaz, Anas Mugharbil, Tamima Jisr & Ahmad Ibrahim. (2016) Retrospective Analysis on the Use of Amphotericin B Lipid Complex in Neutropenic Cancer Patients with Suspected Fungal Infections in Lebanon, a Single Center Experience and Review of International Guidelines. Frontiers in Medicine 2.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
324
352
.
Juan Pablo Botero Aguirre & Alejandra Maria Restrepo Hamid. (2015) Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Julie Autmizguine, Jeffrey T. Guptill, Michael Cohen-Wolkowiez, Daniel K. BenjaminJrJr & Edmund V. Capparelli. (2014) Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications. Drugs 74:8, pages 891-909.
Crossref
Crossref
Hongbo Yang, Paresh Chaudhari, Zheng-Yi Zhou, Eric Q. Wu, Chad Patel & David L. Horn. (2014) Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States. Applied Health Economics and Health Policy 12:1, pages 85-93.
Crossref
Crossref
Alison G. Freifeld & Daniel R. Kaul. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
562
580.e5
.
Rolin L. Wade, Paresh Chaudhari, Jaime L. Natoli, Robert J. Taylor, Brian H. Nathanson & David L. Horn. (2013) Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagnostic Microbiology and Infectious Disease 76:3, pages 361-367.
Crossref
Crossref
Iman Karimzadeh, Hossein Khalili, Shadi Farsaei, Simin Dashti-Khavidaki & Mohammad Mahdi Sagheb. (2013) Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. European Journal of Clinical Pharmacology 69:7, pages 1351-1368.
Crossref
Crossref
Richard J. Hamill. (2013) Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs 73:9, pages 919-934.
Crossref
Crossref
Werner J. Heinz & Florian Weissinger. (2012) Frühe antimykotische Therapiestrategien: empirisch oder diagnostisch gesteuert?. Mycoses 55, pages 17-24.
Crossref
Crossref
P. M. Honoré, R. Jacobs & H. D. Spapen. 2012. Annual Update in Intensive Care and Emergency Medicine 2012. Annual Update in Intensive Care and Emergency Medicine 2012
337
344
.
C. Lass-Flörl, M.C. Arendrup, J.-L. Rodriguez-Tudela, M. Cuenca-Estrella, P. Donnelly & W. Hope. (2011) EUCAST Technical note on Amphotericin B. Clinical Microbiology and Infection 17:12, pages E27-E29.
Crossref
Crossref
Matteo Bassetti, Franco Aversa, Filippo Ballerini, Fabio Benedetti, Alessandro Busca, Nicola Cascavilla, Ercole Concia, Andrea Tendas, Francesco Di Raimondo, Patrizio Mazza, Anna Maria Nosari & Giuseppe Rossi. (2011) Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. Clinical Drug Investigation 31:11, pages 745-758.
Crossref
Crossref
Aryun Kim, David P. Nicolau & Joseph L. Kuti. (2011) Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 54:5, pages e301-e312.
Crossref
Crossref
Jenna J. Ferrara, Conan MacDougall & Jason C. Gallagher. (2012) Empiric Antifungal Therapy in Patients with Febrile Neutropenia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:4, pages 369-385.
Crossref
Crossref
P. Chandrasekar. (2010) Management of invasive fungal infections: a role for polyenes. Journal of Antimicrobial Chemotherapy 66:3, pages 457-465.
Crossref
Crossref
Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young & John R. Wingard. (2011) Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 52:4, pages 427-431.
Crossref
Crossref
Helen V Worthington, Jan E Clarkson, Tasneem Khalid, Stefan Meyer & Martin McCabe. (2010) Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Amar Safdar, Jonathan Ma, Fouzi Saliba, Bertrand Dupont, John R. Wingard, Ray Y. Hachem, Gloria N. Mattiuzzi, Pranatharthi H. Chandrasekar, Dimitrios P. Kontoyiannis, Kenneth V. Rolston, Thomas J. Walsh, Richard E. Champlin & Issam I. Raad. (2010) Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B. Medicine 89:4, pages 236-244.
Crossref
Crossref
Jiun-Ling Wang, Chia-Hsuin Chang, Yinong Young-Xu & K. Arnold Chan. (2010) Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy 54:6, pages 2409-2419.
Crossref
Crossref
Richard Drew. 2009. Antifungal Therapy. Antifungal Therapy
163
183
.
Melissa Corey. (2008) Modern antifungal therapy for neutropenic fever. Current Infectious Disease Reports 11:1, pages 29-34.
Crossref
Crossref
Andreas H. Groll & Thomas J. Walsh. 2008.
Aspergillus fumigatus
and Aspergillosis
.
Aspergillus fumigatus
and Aspergillosis
389
415
.
Elad Goldberg, Anat Gafter-Gvili, Eyal Robenshtok, Leonard Leibovici & Mical Paul. (2008) Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. European Journal of Cancer 44:15, pages 2192-2203.
Crossref
Crossref
Wiro B. Stam, Franco Aversa, Ritesh N. Kumar & Jeroen P. Jansen. (2008) Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy. Value in Health 11:5, pages 830-841.
Crossref
Crossref
C. O. Morrissey, P. G. Bardy, M. A. Slavin, M. R. Ananda-Rajah, S. C. Chen, S. W. Kirsa, D. S. Ritchie & A. Upton. (2008) Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. Internal Medicine Journal 38:6b, pages 477-495.
Crossref
Crossref
John Mohr, Melissa Johnson, Travis Cooper, James S. Lewis & Luis Ostrosky‐Zeichner. (2012) Current Options in Antifungal Pharmacotherapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:5, pages 614-645.
Crossref
Crossref
Ray Y. Hachem, Maha R. Boktour, Hend A. Hanna, Rola N. Husni, Harrys A. Torres, Claude Afif, Dimitrios P. Kontoyiannis & Issam I. Raad. (2008) Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112:6, pages 1282-1287.
Crossref
Crossref
Alison G. Freifeld & Daniel R. Kaul. 2008. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
717
737
.
Oscar Marchetti, Catherine Cordonnier & Thierry Calandra. (2007) Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. European Journal of Cancer Supplements 5:2, pages 32-42.
Crossref
Crossref
Melissa Corey. (2008) Modern antifungal therapy for neutropenic fever. Current Fungal Infection Reports 1:1, pages 19-24.
Crossref
Crossref
Helen V Worthington, Jan E Clarkson & Tim OB Eden. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
John R. Wingard, Helen L. Leather, Craig A. Wood, William C. Gerth, Robert J. Lupinacci, Marc L. Berger & Edward C. Mansley. (2007) Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. American Journal of Health-System Pharmacy 64:6, pages 637-643.
Crossref
Crossref
F. Botterel. (2007) Démarche diagnostique et prise en charge des infections fongiques chez les patients immunodéprimés. Antibiotiques 9:1, pages 34-43.
Crossref
Crossref
Saman Kannangara. (2006) Management of febrile neutropenia. Community Oncology 3:9, pages 585-591.
Crossref
Crossref
Zhihua Zhang, Robert M. Diener & Jack M. Lipman. (2016) Safety Evaluation of ABELCET, an Amphotericin B Lipid Complex (ABLC): Toxicity Studies in Rats. International Journal of Toxicology 25:4, pages 285-294.
Crossref
Crossref
Melissa Corey. (2006) Modern antifungal therapy for neutropenic fever. Current Hematologic Malignancy Reports 1:2, pages 95-100.
Crossref
Crossref
J. Pachl, P. Svoboda, F. Jacobs, K. Vandewoude, B. van der Hoven, P. Spronk, G. Masterson, M. Malbrain, M. Aoun, J. Garbino, J. Takala, L. Drgona, J. Burnie & R. Matthews. (2006) A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis. Clinical Infectious Diseases 42:10, pages 1404-1413.
Crossref
Crossref
Marie-Dominique Tabone, Nathalie Le Guyader & Guy Leverger. (2006) Spécificités pédiatriques de l’utilisation des antifongiques. Therapies 61:3, pages 243-248.
Crossref
Crossref
S. B. Girois, F. Chapuis, E. Decullier & B. G. P. Revol. (2006) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 25:2, pages 138-149.
Crossref
Crossref
B. J. Spellberg, S. G. Filler & J. E. Edwards. (2006) Current Treatment Strategies for Disseminated Candidiasis. Clinical Infectious Diseases 42:2, pages 244-251.
Crossref
Crossref
Rodrigo Martino & Claudio Viscoli. (2005) Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. British Journal of Haematology 132:2, pages 138-154.
Crossref
Crossref
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
192
211
.
P. Svoboda & I. Kantorová. 2006. Yearbook of Intensive Care and Emergency Medicine. Yearbook of Intensive Care and Emergency Medicine
595
603
.
P. Svoboda & I. Kantorová. 2006. Intensive Care Medicine. Intensive Care Medicine
595
603
.
M.Teresa Olivé-Oliveras & Isabel Ruiz-Camps. (2005) Consideraciones especiales de la neutropenia febril en el paciente pediátrico. Enfermedades Infecciosas y Microbiología Clínica 23, pages 35-39.
Crossref
Crossref
A. Antoniadou & B. Dupont. (2005) Lipid formulations of amphotericin B: where are we today?. Journal de Mycologie Médicale 15:4, pages 230-238.
Crossref
Crossref
J. R. Wingard & H. Leather. (2005) Hepatotoxicity Associated with Antifungal Therapy after Bone Marrow Transplantation. Clinical Infectious Diseases 41:3, pages 308-310.
Crossref
Crossref
Barbara D. Alexander & John R. Wingard. (2005) Study of Renal Safety in Amphotericin B Lipid Complex–Treated Patients. Clinical Infectious Diseases 40:Supplement_6, pages S414-S421.
Crossref
Crossref
S. Alfandari, O. Leroy, S. de Botton, I. Yakoub-Agha, I. Durand-Joly, A. Leroy-Cotteau & G. Beaucaire. (2005) Prise en charge diagnostique et thérapeutique des infections à Aspergillus sp. chez le patient immunodéprimé. Recommandations du CHRU de Lille — version 4 — novembre 2004. Médecine et Maladies Infectieuses 35:3, pages 121-134.
Crossref
Crossref
S. B. Girois, F. Chapuis, E. Decullier & B. G. P. Revol. (2005) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 24:2, pages 119-130.
Crossref
Crossref
John R. Wingard. (2004) Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Clinical Infectious Diseases 39:s1, pages S38-S43.
Crossref
Crossref
Maricel Subirà, Rodrigo Martino, Lucia Gómez, Josep María Martí, Cristina Estany & Jorge Sierra. (2004) Low-dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. European Journal of Haematology 72:5, pages 342-347.
Crossref
Crossref
M. A. Slavin, J. Szer, A. P. Grigg, A. W. Roberts, J. F. Seymour, J. Sasadeusz, K. Thursky, S. C. Chen, C. O. Morrissey, C. H. Heath & And T. Sorrell. (2004)
Guidelines for the use of antifungal agents in the treatment of invasive
Candida
and mould infections
. Internal Medicine Journal 34:4, pages 192-200.
Crossref
Crossref
John R Wingard & Helen Leather. (2004) A new era of antifungal therapy. Biology of Blood and Marrow Transplantation 10:2, pages 73-90.
Crossref
Crossref
Gloria N. Mattiuzzi, Hagop Kantarjian, Stefan Faderl, JoAnn Lim, Dimitrios Kontoyiannis, Deborah Thomas, William Wierda, Isaam Raad, Guillermo Garcia‐Manero, Xian Zhou, Alexandra Ferrajoli, Nebiyou Bekele & Elihu Estey. (2004) Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:3, pages 581-589.
Crossref
Crossref
JE Clarkson, HV Worthington & OB Eden. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Joseph L Kuti, Srividya Kotapati, Peter Williams, Blair Capitano, Charles H Nightingale & David P Nicolau. (2004) Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal Infections. PharmacoEconomics 22:5, pages 301-310.
Crossref
Crossref
Peter K. Linden, Kim Coley, Paolo Fontes, John J. Fung & Shimon Kusne. (2003) Invasive Aspergillosis in Liver Transplant Recipients: Outcome Comparison of Therapy with Amphotericin B Lipid Complex and a Historical Cohort Treated with Conventional Amphotericin B. Clinical Infectious Diseases 37:1, pages 17-25.
Crossref
Crossref
Romuald Bellmann, Petra Egger & Christian J. Wiedermann. (2003) Differences in Pharmacokinetics of Amphotericin B Lipid Formulations Despite Clinical Equivalence. Clinical Infectious Diseases 36:11, pages 1500-1501.
Crossref
Crossref
Jane P. Barrett, Katerina A. Vardulaki, Christopher Conlon, Jonathan Cooke, Pascual Daza-Ramirez, E.Glyn V. Evans, Peter M. Hawkey, Raoul Herbrecht, David I. Marks, Jose M. Moraleda, Gilbert R. Park, Stephen J. Senn & Claudio Viscoli. (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clinical Therapeutics 25:5, pages 1295-1320.
Crossref
Crossref
D.P. Kontoyiannis, E. Mantadakis & G. Samonis. (2003) Systemic mycoses in the immunocompromised host: an update in antifungal therapy. Journal of Hospital Infection 53:4, pages 243-258.
Crossref
Crossref
Andreas H. Groll & Thomas J. Walsh. 2003.
302
314
.
Joan Gavaldà & Isabel Ruiz. (2003) Recomendaciones para el tratamiento de la infección fúngica invasiva. Infeccion fúngica invasiva por Candida spp.. Enfermedades Infecciosas y Microbiología Clínica 21:9, pages 498-508.
Crossref
Crossref
Walter Hughes, Donald Armstrong, Gerald Bodey, Eric Bow, Arthur Brown, Thierry Calandra, Ronald Feld, Philip Pizzo, Kenneth Rolston, Jerry Shenep & Lowell Young. (2002) Reply. Clinical Infectious Diseases 35:7, pages 897-898.
Crossref
Crossref
Richard Frothingham. (2002) Lipid Formulations of Amphotericin B for Empirical Treatment of Fever and Neutropenia. Clinical Infectious Diseases 35:7, pages 896-897.
Crossref
Crossref
John R. Wingard. (2002) Lipid Formulations of Amphotericins: Are You a Lumper or a Splitter?. Clinical Infectious Diseases 35:7, pages 891-895.
Crossref
Crossref
Brad Spellberg & John E. EdwardsJrJr. (2002) The pathophysiology and treatment of Candida sepsis. Current Infectious Disease Reports 4:5, pages 387-399.
Crossref
Crossref
G Inselmann, U Inselmann & H.T Heidemann. (2002) Amphotericin B and liver function. European Journal of Internal Medicine 13:5, pages 288-292.
Crossref
Crossref
Walter T. Hughes, Donald Armstrong, Gerald P. Bodey, Eric J. Bow, Arthur E. Brown, Thierry Calandra, Ronald Feld, Philip A. Pizzo, Kenneth V. I. Rolston, Jerry L. Shenep & Lowell S. Young. (2002) 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clinical Infectious Diseases 34:6, pages 730-751.
Crossref
Crossref
Thomas J. Walsh, Jesse L. GoodmanPeter PappasIhor Bekersky, Donald N. Buell, Maureen Roden, John BarrettElias J. Anaissie. (2001)
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with
Aspergillus
Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
. Antimicrobial Agents and Chemotherapy 45:12, pages 3487-3496.
Crossref
Crossref